[go: up one dir, main page]

WO2013016720A3 - Nouveaux dérivés biaryl-hétérocycliques substitués en tant qu'inhibiteurs de protéine kinase pour le traitement du cancer et d'autres maladies - Google Patents

Nouveaux dérivés biaryl-hétérocycliques substitués en tant qu'inhibiteurs de protéine kinase pour le traitement du cancer et d'autres maladies Download PDF

Info

Publication number
WO2013016720A3
WO2013016720A3 PCT/US2012/048741 US2012048741W WO2013016720A3 WO 2013016720 A3 WO2013016720 A3 WO 2013016720A3 US 2012048741 W US2012048741 W US 2012048741W WO 2013016720 A3 WO2013016720 A3 WO 2013016720A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein kinase
diseases
biarylheterocycle
cancer
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/048741
Other languages
English (en)
Other versions
WO2013016720A2 (fr
Inventor
Magnus Pfahl
F. Javier PIEDRAFITA
Laxman Rao Cilamkoti VENKAT
Venugopal Rao VEERAMANENI
Bhaskar Venepalli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GERINDA THERAPEUTICS Inc
Original Assignee
GERINDA THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GERINDA THERAPEUTICS Inc filed Critical GERINDA THERAPEUTICS Inc
Publication of WO2013016720A2 publication Critical patent/WO2013016720A2/fr
Publication of WO2013016720A3 publication Critical patent/WO2013016720A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une nouvelle classe brevetable de composés dérivés de benzoxazole substitués qui présentent une activité inhibitrice ou une capacité de modulation de protéine kinase (PK), ainsi que des compositions et procédés d'utilisation de tels composés, par exemple, pour prévenir ou traiter diverses maladies et divers troubles chez des êtres humains et des animaux non humains.
PCT/US2012/048741 2011-07-28 2012-07-28 Nouveaux dérivés biaryl-hétérocycliques substitués en tant qu'inhibiteurs de protéine kinase pour le traitement du cancer et d'autres maladies Ceased WO2013016720A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512882P 2011-07-28 2011-07-28
US61/512,882 2011-07-28

Publications (2)

Publication Number Publication Date
WO2013016720A2 WO2013016720A2 (fr) 2013-01-31
WO2013016720A3 true WO2013016720A3 (fr) 2013-03-28

Family

ID=47601783

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/048741 Ceased WO2013016720A2 (fr) 2011-07-28 2012-07-28 Nouveaux dérivés biaryl-hétérocycliques substitués en tant qu'inhibiteurs de protéine kinase pour le traitement du cancer et d'autres maladies

Country Status (1)

Country Link
WO (1) WO2013016720A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3521291A1 (fr) 2010-05-20 2019-08-07 Array Biopharma, Inc. Composés macrocycliques comme inhibiteurs de la kinase trk
KR20180041135A (ko) 2015-07-16 2018-04-23 어레이 바이오파마 인크. Ret 키나아제 억제제로서 치환된 피라졸로[1,5-a]피리딘 화합물
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (fr) 2017-01-18 2018-07-26 Array Biopharma, Inc. Inhibiteurs de ret
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TW201932464A (zh) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143991A1 (fr) 2018-01-18 2019-07-25 Array Biopharma Inc. Composés de pyrazolo[3,4-d]pyrimidine substitués utilisés en tant qu'inhibiteurs de la kinase ret
WO2020055672A1 (fr) 2018-09-10 2020-03-19 Array Biopharma Inc. Composés hétérocycliques condensés comme inhibiteurs de kinases ret
CN116253686B (zh) * 2022-12-09 2023-11-17 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 氨基苯并咪唑苯甲酰胺类衍生物及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2262932C2 (ru) * 2000-12-15 2005-10-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы гиразы бактерий и их применения
WO2009156966A1 (fr) * 2008-06-25 2009-12-30 Ranbaxy Laboratories Limited Benzothiazoles et leurs analogues aza utilisés comme agents antibactériens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2262932C2 (ru) * 2000-12-15 2005-10-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы гиразы бактерий и их применения
WO2009156966A1 (fr) * 2008-06-25 2009-12-30 Ranbaxy Laboratories Limited Benzothiazoles et leurs analogues aza utilisés comme agents antibactériens

Also Published As

Publication number Publication date
WO2013016720A2 (fr) 2013-01-31

Similar Documents

Publication Publication Date Title
WO2013016720A3 (fr) Nouveaux dérivés biaryl-hétérocycliques substitués en tant qu'inhibiteurs de protéine kinase pour le traitement du cancer et d'autres maladies
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
EA201490545A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ С-Kit
MY167245A (en) Compounds and compositions as c-kit kinase inhibitors
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
WO2011014795A3 (fr) Composés et compositions pouvant servir d'inhibiteurs de la kinase syk
WO2014031928A3 (fr) Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
EA201490542A1 (ru) Соединения и композиции в качестве pdgfr киназных ингибиторов
MX342509B (es) Compuestos de indazol sustituidos como inhibidores de las cinasas de proteina.
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
EA201490539A1 (ru) Соединения и композиции в качестве ингибиторов c-kit киназы
WO2014031933A3 (fr) Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
WO2014031936A3 (fr) Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies
IN2015DN01151A (fr)
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
EA201390520A1 (ru) Замещенные соединения пиридазинкарбоксамида
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors
MX2014002343A (es) Inhibidores de parp.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12818072

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12818072

Country of ref document: EP

Kind code of ref document: A2